Virendra Sharma, MD
Hospitalist · Utica, NYNPI 1003807041
Payments from drug & device makers
Across 186 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$638
- Pfizer$504
- AstraZeneca$430
- Lilly USA, LLC$236
- Johnson & Johnson$157
- Abbott$152
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,386100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $638 |
| Pfizer | 29 | $504 |
| AstraZeneca | 25 | $430 |
| Lilly USA, LLC | 15 | $236 |
| Johnson & Johnson | 4 | $157 |
| Abbott | 8 | $152 |
| Novo Nordisk | 9 | $151 |
| Amgen | 10 | $151 |
| AbbVie(2 entities) | 8 | $141 |
| Boehringer Ingelheim | 5 | $88 |
| Gilead | 4 | $81 |
| Novartis | 5 | $76 |
| Merck | 5 | $73 |
| Dynavax Technologies Corporation | 3 | $62 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| CSL Behring | 1 | $37 |
| Smith+Nephew | 2 | $36 |
| Lundbeck LLC | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$110
How this compares
$3,386 in reported general payments places this provider in the 95th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $95,004 |
| JanuviaSitagliptin Phosphate | 50 | $63,127 |
| JardianceEmpagliflozin | 27 | $35,721 |
| FarxigaDapagliflozin Propanediol | 20 | $32,795 |
| OzempicSemaglutide | 21 | $31,128 |
| XareltoRivaroxaban | 22 | $30,473 |
| EntrestoSacubitril/Valsartan | 21 | $23,368 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,744 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,761 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $5,575 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 125 | $4,712 |
| Pregabalin | 39 | $4,481 |
| Metoprolol Succinate | 207 | $3,945 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $3,016 |
| Rosuvastatin Calcium | 203 | $2,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $504 | $95,00485 claims |
| MerckJanuvia | $73 | $63,12750 claims |
| Boehringer IngelheimJardiance | $88 | $35,72127 claims |
| AstraZenecaFarxiga | $430 | $32,79520 claims |
| Novo NordiskOzempic | $151 | $31,12821 claims |
| Johnson & JohnsonXarelto | $157 | $30,47322 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $638 | $26,50531 claims |
| NovartisEntresto | $76 | $23,36821 claims |
| AbbVieSynthroid | $141 | $1,55917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,860 hospitalist providers in New York.
Other hospitalist in Utica
- Mark GoldinNew Hyde Park$666K
- Nelson Chan-HungRochester$445K
- Zainab Mogul-AshrafMiddletown$393K
- Manika SuryadevaraSyracuse$322K
- Saquib RahimFlushing$239K
- Saadia SheraziRochester$102K
- Salman AzimRochester$88K
- Farrukh AbbasRochester$84K
- Usman SiddiquiNyack$70K
- Amit NarayanNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.